Myriad Genetics, Inc. MYGN shares are trading higher by 12.4% at $34.68 Tuesday afternoon after the company reported better-than-expected fourth-quarter EPS and sales results.
Myriad Genetics reported quarterly earnings of 12 cents per share which beat the analyst consensus estimate of a loss of 7 cents per share. The company reported quarterly sales of $189.40 million which beat the analyst consensus estimate of $166.73 million.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer.
Myriad Genetics has a 52-week high of $34.96 and a 52-week low of $11.76.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
